Visceral obesity and metabolic syndrome.
There is increasing evidence for the existence of a condition consisting of a cluster of metabolic disorders which include insulin resistance, alterations in glucose and lipid metabolism, increased blood pressure and visceral obesity. The metabolic syndrome is now the favoured definition of the cluster. Each single component of the cluster increases the cardiovascular risk, but the combination of factors is much more important. Insulin resistance is the most frequently associated factor to the singular components of the syndrome: most authors believe that it may be the common aetiological factor. However, visceral obesity seems to be the main driving factor by means of the increased production of free fatty acids whose activity, in turn, might interfere with the action of insulin. Some questions exist about the syndrome because of the frequent lack in the cluster of one of the factors. This does not mean that the missing factor does not belong to the syndrome, but only that it is not yet clinically evident. Weight gain has been shown to be a strong predictor of the metabolic syndrome. This aspect gives strength to treatment and prevention because it means that losing weight or stopping weight increase might reduce the risk of a future appearance of a factor that is still not evident. Interventions to treat visceral obesity by means of losing weight seem to be the most efficacious way to treat the metabolic syndrome thus improving the most widespread cardiovascular risk factor in western countries.
Bosello
O
O
Department of Biomedical and Surgical Sciences, University of Verona, Piazza Stefani, 1-37126, Verona, Italy. bosello@borgotrento.univr.it
Zamboni
M
M
D000273:Adipose Tissue; D001823:Body Composition; D001824:Body Constitution; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D018149:Glucose Intolerance / Q000150:complications; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications; D006973:Hypertension / Q000150:complications; D007333:Insulin Resistance; D024821:Metabolic Syndrome; D009765:Obesity / Q000150:complications; D014781:Viscera
D005230:Fatty Acids, Nonesterified